


The use of lateral flow urine  
lipoarabinomannan assay (LF-LAM)  
for the diagnosis and screening  
of active tuberculosis in people living with HIV



**The use of lateral flow urine  
lipoarabinomannan assay (LF-LAM)  
for the diagnosis and screening  
of active tuberculosis in people living  
with HIV**

**Policy guidance**

## **WHO Library Cataloguing-in-Publication Data**

The use of lateral flow urine lipoarabinomannan assay (LF-LAM) for the diagnosis and screening of active tuberculosis in people living with HIV. Policy guidance.

I. World Health Organization.

ISBN 978 92 4 150963 3

Subject headings are available from WHO institutional repository

## **© World Health Organization 2015**

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website ([www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by GPS Publishing

Printed by the WHO Document Production Services, Geneva, Switzerland

WHO/HTM/TB/2015.25

## Contents

<b>Executive summary.....</b>	<b>1</b>
<b>1. Background .....</b>	<b>3</b>
<b>2. Methods .....</b>	<b>6</b>
2.1. Evidence synthesis .....	6
2.2. Guideline Development Group meeting .....	9
2.3. External Review Group .....	10
<b>3. Scope .....</b>	<b>11</b>
3.1. Target audience.....	11
<b>4. Evidence base for policy formulation.....</b>	<b>12</b>
4.1. Quality of included studies.....	13
4.2. LF-LAM accuracy for the diagnosis of active TB in people living with HIV....	14
4.2.1. Overall accuracy of LF-LAM compared with a microbiological reference standard.....	14
4.2.2. Overall accuracy of LF-LAM compared with a composite reference standard.....	15
4.2.3. LF-LAM accuracy by health care setting.....	15
4.2.4. LF-LAM for the diagnosis of TB in adults living with HIV by CD4 threshold.....	16
4.2.5. LF-LAM compared to conventional tests for the diagnosis of TB in adults .....	19
4.2.6. LF-LAM for the diagnosis of TB in children living with HIV compared with a microbiological reference standard .....	21
4.3. LF-LAM for screening of active TB in people living with HIV .....	21
4.3.1. Overall accuracy of LF-LAM to screen for TB in adults living with HIV compared with a microbiological reference standard .....	21
4.3.2. Overall accuracy of LF-LAM to screen for TB in adults living with HIV compared with a composite reference standard .....	22
4.3.3. LF-LAM for screening for TB in adults living with HIV by health care setting.....	22
4.3.4. LF-LAM for screening for TB in adults living with HIV by CD4 threshold .....	23
4.4. LF-LAM and patient outcomes .....	23
4.5. Cost and cost-effectiveness of using LF-LAM for the diagnosis of active TB .....	24

4.6. Inter- and intra-reader variability between test readers in studies, included in the review .....	25
<b>5. Summary of evidence to recommendations.....</b>	<b>26</b>
5.1. LF-LAM for the diagnosis of active TB .....	26
5.2. LF-LAM for the screening for TB.....	27
<b>6. WHO policy recommendations .....</b>	<b>28</b>
<b>7. Implementation considerations .....</b>	<b>29</b>
7.1. Plans for disseminating the WHO policy guidance on LF-LAM .....	29
<b>8. Research needs.....</b>	<b>30</b>
<b>9. Grade tables .....</b>	<b>31</b>
<b>10. Annexes.....</b>	<b>50</b>
Annex 1. Meeting participants .....	50
Annex 2. Members of the External Review Group .....	51
Annex 3 WHO Steering Group.....	52
Annex 4. Declarations of Interests .....	52
Annex 5. References to studies for the review of the diagnostic accuracy of LF-LAM .....	53
Annex 6. References to studies for the review of economic evaluations of LF-LAM .....	59
Annex 7. Summaries of unpublished studies included in the review .....	62

Tables	
<b>Table 1.</b>	Summary of LF-LAM diagnostic accuracy for active TB at different CD4 thresholds ..... 17
<b>Table 2</b>	GRADE evidence profile: accuracy of LF-LAM to diagnose tuberculosis in adults with HIV, microbiological reference standard, grade 2 ..... 31
<b>Table 3</b>	GRADE evidence profile: accuracy of LF-LAM to diagnose tuberculosis in adults with HIV, composite reference standard, grade 2 ..... 32
<b>Table 4</b>	GRADE evidence profile: accuracy of LF-LAM to diagnose tuberculosis in children with HIV ..... 33
<b>Table 5</b>	GRADE evidence profile: accuracy of LF-LAM to diagnose tuberculosis in adults with HIV in inpatient setting, grade 2 ..... 34
<b>Table 6</b>	GRADE evidence profile: accuracy of LF-LAM to diagnose tuberculosis in adults with HIV in outpatient setting, grade 2 ..... 35
<b>Table 7</b>	GRADE evidence profile: accuracy of LF-LAM to diagnose tuberculosis in adults with HIV with CD4 > 200 cells/μL, grade 2 ..... 36
<b>Table 8</b>	GRADE evidence profile: accuracy of LF-LAM to diagnose tuberculosis in adults with HIV with CD4 ≤ 200 cells/μL, grade 2 ..... 37
<b>Table 9</b>	GRADE evidence profile: accuracy of LF-LAM to diagnose tuberculosis in adults with HIV with CD4 > 100 cells/μL, grade 2 ..... 38
<b>Table 10</b>	GRADE evidence profile: accuracy of LF-LAM to diagnose tuberculosis in adults with HIV with CD4 ≤ 100 cells/μL, grade 2 ..... 39
<b>Table 11</b>	GRADE evidence profile: accuracy of LF-LAM to diagnose tuberculosis in adults with HIV with CD4 ≤ 200 cells/μL in inpatient settings, grade 2 ..... 40
<b>Table 12</b>	GRADE evidence profile: accuracy of LF-LAM to diagnose tuberculosis in adults with HIV with CD4 ≤ 100 cells/μL in inpatient settings, grade 2 ..... 41
<b>Table 13</b>	GRADE evidence profile: accuracy of LF-LAM vs. sputum microscopy to diagnose tuberculosis in adults with HIV, grade 2 ..... 42
<b>Table 14</b>	GRADE evidence profile: accuracy of LF-LAM in combination with sputum microscopy to diagnose tuberculosis in adults with HIV, grade 2 ..... 43
<b>Table 15</b>	GRADE evidence profile: accuracy of LF-LAM vs. sputum Xpert MTB/RIF microscopy to diagnose tuberculosis in adults with HIV, grade 2 ..... 44
<b>Table 16</b>	GRADE evidence profile: accuracy of LF-LAM in combination with sputum Xpert MTB/RIF microscopy to diagnose tuberculosis in adults with HIV, grade 2 ..... 45
<b>Table 17</b>	GRADE evidence profile: accuracy of LF-LAM to screen for tuberculosis in adults with HIV, grade 2 ..... 46

**Table 18** GRADE evidence profile: accuracy of LF-LAM to screen for tuberculosis in adults with HIV, composite reference standard, grade 2..... 47

**Table 19** GRADE evidence profile: accuracy of LF-LAM to screen for tuberculosis in adults with HIV in inpatient setting, grade 2..... 48

**Table 20** GRADE evidence profile: accuracy of LF-LAM to screen for tuberculosis in adults with HIV in outpatient setting, grade 2 ..... 49

Figures

**Figure 1** Alere Determine™ TB LAM Ag test ..... 4

**Figure 2** Grading of Determine TB Ag assay ..... 5

**Figure 3** Selection of studies evaluating the accuracy of LF-LAM for the diagnosis of active TB: flow diagram of studies identified by the literature ..... 13

**Figure 4** Risk of bias and applicability concerns graph: judgements about each domain presented as percentages across the 16 included studies ..... 14

**Figure 5** Forest plots of sensitivity and specificity of LF-LAM for diagnosis of active TB in people living with HIV against a microbiological reference standard ..... 14

**Figure 6** Forest plot of the sensitivity and specificity of LF-LAM for diagnosis of active TB in people living with HIV against a composite reference standard ..... 15

**Figure 7** Forest plots of sensitivity and specificity of LF-LAM for diagnosis of active TB against a microbiological reference standard, HIV positive inpatients ..... 16

**Figure 8** Forest plots of the sensitivity and specificity of LF-LAM for diagnosis of active TB against a microbiological reference standard, HIV positive outpatients ..... 16

**Figure 9** Forest plots of sensitivity and specificity of LF-LAM for diagnosis of active TB in HIV positive patients with CD4 count > 200 cells/μL, microbiological reference standard ..... 17

**Figure 10** Forest plots of sensitivity and specificity of LF-LAM for diagnosis of active TB in HIV positive patients with CD4 count ≤ 200 cells /μL, microbiological reference standard ..... 18

预览已结束，完整报告链接

<https://www.yunbaogao.cn/report/index/rep>